Digital Biomanufacturing Market Growth

The Digital Biomanufacturing Market Growth is anticipated at a CAGR of 18%; Market Value to Grow to USD 12 Billion till 2035 | Roots Analysis

According to a recently published report by Roots Analysis, increasing adoption of digitalization in the biomanufacturing industry, driven by its advantages in achieving process automation, real-time monitoring, data analytics and process optimization, is driving the digital biomanufacturing market growth

Digital Biomanufacturing Industry Overview

The global digital biomanufacturing market size is estimated to reach USD 12.0 billion by 2035, representing a higher CAGR of 18% in the forecast period.

Digital biomanufacturing encompass a diverse array of technologies, including process analytical technology (PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twins. Biopharmaceutical companies integrate these tools to achieve operational excellence, visibility, control and synchronization in bioprocessing with an aim to improve yield in faster timelines. Further, digital biomanufacturing employs various manufacturing principles, such as computer-aided design, real-time monitoring and process validation, for improving the overall biological manufacturing process. Notably, the increasing demand for biologics and challenges associated with handling complex datasets have spurred the need for digitally integrated solutions. As a result, the emergence of digital biomanufacturing holds promise as a viable alternative to address various concerns in bioprocessing. Moreover, it also plays a significant role in enhancing process robustness and ensuring product quality. Owing to these factors, the global digital biomanufacturing market is expected to grow significantly during the forecast period.

Browse 145+ figures and 170+ market data tables and detailed Table of Content on “Digital Biomanufacturing Market” by Distribution by Type of Technology (Manufacturing Execution Systems, Process Analytical Technologies, Data Analytics Software and Digital Twins), Deployment Option (Cloud-based Deployment and On-premises Deployment), Scale of Operation (Commercial Scale and Clinical Scale), Type of Biologic Manufactured (Antibodies, Peptides, Cell and Gene Therapies and Other Biologics), End Users (In-house Developers, Contract Manufacturers and Both End Users) and Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America): Industry Trends and Global Forecasts, till 2035” here: https://www.rootsanalysis.com/reports/digital-biomanufacturing-market.html

Market Drivers

Several factors are propelling the digital biomanufacturing market growth. The reliance on conventional biomanufacturing operations has put significant pressure on the biopharmaceutical industry to produce high quality biologics with improved yield in shorter time duration. The digital biomanufacturing solutions have emerged as a promising alternative over these traditional manufacturing processes, offering various advantages including real-time process monitoring, and reduced batch-to-batch variability. These advantages contribute to increased product quality, reduced manufacturing cost, decreased process variability and shorter operational timelines. As a result, digital biomanufacturing is being widely explored for the development and production of vaccines, antibodies and cell and gene therapies.

Market Restraints

While the digital biomanufacturing market is experiencing substantial growth, it is not without its challenges. One of the primary restraints in this domain is high cost associated with integration of advanced digital technologies, such as artificial intelligence, machine learning, internet of things and cloud-based solutions. In addition to this, since digital biomanufacturing relies heavily on advanced data analytics and automation, the technology providers must manage and safeguard large volumes of sensitive data and hence, might face privacy and security risks. It is important to mention that, despite the significant progress made towards the adoption of digital technologies in biologics manufacturing, the biopharmaceutical industry has not fully embraced these advancements. This can be attributed to lack of technical expertise in this field, which is further hindering the implantation of digital solutions. Consequently, such challenges pose significant restraint for the digital biomanufacturing domain.

Growth Factors

Despite the challenges, several factors continue to drive the digital biomanufacturing market growth forward. In the past few years, the exponential increase in biologics approval has underscored an urgent need for innovation in this field in order to cater to the rising demand for high-quality, scalable biologics production. Further, biopharmaceutical companies have shifted their focus towards adoption of advanced technologies in digital biomanufacturing, including artificial intelligence (AI) and digital twins for predictive simulations. Through these initiatives, the companies aim to enhance operational excellence, process control, and achieve synchronization across bioprocessing workflows. As a result, the digital biomanufacturing market is poised to offer lucrative opportunities for technology providers in the coming years.

Digital Biomanufacturing Market Segments

Based on the type of technology, the market is segmented into manufacturing execution systems, process analytical technologies, data analytics software and digital twins

• The manufacturing execution systems segment is likely to capture the largest revenue share of close to 35% in the digital biomanufacturing market, in the current year.
• The process analytical technologies segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 18.6%, during the forecast period.

Based on deployment mode, the market is segmented into cloud-based deployment and on-premises deployment

• The on-premises deployment segment is likely to capture the largest revenue share of around 70% in the digital biomanufacturing market, in the current year.
• The cloud-based deployment segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.4%, during the forecast period.

Based on the scale of operation, the market is segmented into commercial and clinical scale

• The commercial scale segment is likely to capture the largest revenue share of close to 90% in the digital biomanufacturing market, in the current year.
• The clinical scale segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 20.5%, during the forecast period.

Based on the type of biologic manufactured, the market is segmented into antibodies, peptides, cell and gene therapies, and other biologics

• The antibodies segment is likely to capture the largest revenue share of more than 65% in the digital biomanufacturing market, in the current year.
• The cell and gene therapies segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 29.2%, during the forecast period.

Based on end users, the market is segmented into in-house developers, contract manufacturers and both end users

• The in-house developers segment is likely to capture the largest revenue share of 65% in the digital biomanufacturing market, in the current year.
• The contract manufacturers segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 20.2%, during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America

• Europe is expected to dominate the digital biomanufacturing market, accounting for the largest revenue share (close to 40%) in the current year.
• In Asia-Pacific, the digital biomanufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

Companies Profiled

The digital biomanufacturing market report also includes profiles of some players (listed below) that are engaged in the digital biomanufacturing domain:

• Apprentice
• AspenTech
• CellPort
• Dassault Systèmes
• Eppendorf
• FUJIFILM Diosynth Biotechnologies
• GE Vernova
• KÖrber
• Merck
• Sartorius
• Siemens
• Striim
• Thermo Fisher Scientific
• Tridiagonal Software
• Vimachem

You Can Download Free Sample PDF Copy of This Report At:

https://www.rootsanalysis.com/reports/digital-biomanufacturing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com